DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Ultrasound Homepage

Fujifilm SonoSite brings new workflow solution to point of care ultrasound Addressing top priorities to reduce administrative burden on providers

New dye helps control 'lighting' for sharper images of heart May help identify early signs of heart disease

Ultrasound market gets supercharged by AI, cloud, and greater portability: report Generated $6.12 billion in 2018, and more growth expected

Verasonics settles legal dispute over software with SuperSonic Imagine Alleged patent infringement and misappropriate of trade secrets

Handheld ultrasound market poised for next wave of growth Insights from the market analysts at Signify Research

VisualDx to develop decision support platform for ultrasound in space Provide basic guidance on ultrasound interpretation

Breaking barriers in Alzheimer’s disease with focused ultrasound Researchers at Sunnybrook in Toronto are closing the therapeutic gap

Purchasing insights for cardiac ultrasound Guidance from the market experts at MD Buyline

Trice Imaging connects imaging devices of large chain healthcare provider Aleris Patients and physicians can view images on laptops, cell phones

New ultrasound tech could help detect pediatric congenital heart disease Visualizes structure and blood flow of babies' hearts

Contrast enhanced ultrasound in pediatric patients

From the March 2018 issue of DOTmed HealthCare Business News magazine

Approximately 30 million people in the U.S. have some form of liver disease. However, its symptoms can be vague and easily confused with other health complications, making it difficult to diagnose.

In April 2016, the FDA approved the use of contrast agent for liver lesion characterization in adult and pediatric patients, offering clinicians a fast way of confidently detecting problems in a patient’s liver, using non-ionizing radiation.
Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.




Our main clinical indication for contrast enhanced ultrasound (CEUS) is to characterize focal liver lesions. Focal liver lesions occur in about 17 percent of children after cancer therapy. When such lesions arise, it is crucial to determine whether they are benign or represent metastatic disease. Before utilizing CEUS at our institution, such patients would undergo additional imaging (often MRI which can require sedation of young patients) or early imaging follow-up to determine the growth rate of the lesion. This approach resulted in added time, cost and anxiety in the patient’s management.



Now these patients undergo CEUS on the same day or the next day after the original imaging exam that discovered the focal liver lesion. This approach is quick, low-cost, uses non-ionizing radiation and is sedation-free. It provides immediate clinical images, which enables physicians to give feedback to the patient, their family and treating physician.

I believe the role of CEUS in pediatric oncology will increase. There are a wide variety of potential applications. In addition to being low-cost and sedation-free, it has the added benefit of being portable. This is an important attribute in our institution because patients needing imaging studies may be too ill to come to the radiology department. The system can be easily transported to their bedside. Children are naturally in motion, so it’s important to be able to capture clear images quickly.

With the introduction of targeted therapies into cancer clinical trials, there is a growing need for functional and metabolic imaging methods that go beyond a simple measurement of tumor size. Dynamic, quantitative contrast enhanced ultrasound may provide a method of assessing tumor blood flow which, in turn, may reflect or predict response to therapy.
Dr. Beth McCarville
This, however, needs to be validated in clinical trials.

About the author: Dr. Beth McCarville is the chief of the Body Imaging Section at St. Jude Children’s Research Hospital.

Back to HCB News
<< Pages: 1 - 2

Ultrasound Homepage


You Must Be Logged In To Post A Comment

La publicité d'email
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Jobs/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Voir les utilisateurs récemment certifiés
Voir les utilisateurs récemment certifiés
Récemment évalué sur DOTmed
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service Technicians Forum
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2019 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS